56 results about "Zanamivir" patented technology

The present invention relates to targets for Human microRNAs in Avian Influenza Virus (H5N1) Genome and provides specific miRNA targets against H5N1 virus. Existing therapies for Avian flu are of limited use primarily due to genetic re-assortment of the viral genome, generating novel proteins, and thus escaping immune response. In animal models, baculovirus-derived recombinant H5 vaccines were immunogenic and protective, but results in humans were disappointing even when using high doses. Currently, two classes of drugs are available with antiviral activity against influenza viruses: inhibitors of the M2 ion channel, amantadine and rimantadine, and inhibitors of neuraminidase, oseltamivir, and zanamivir. There is paucity of information regarding effectiveness of these drugs in H5N1 infection. These drugs are also well known to have side effects like neurotoxicity. Thus there exists a need to develop alternate therapy for targeting the Avian flu virus (H5N1). The present invention addresses this need in the field.

Antimicrobial compositions containing two or more antiviral agents coupled to a polymer and methods of making and using the compositions, are described herein. In one embodiment, two or more antiviral agents are covalently coupled to the polymer. Suitable antiviral agents include, but are not limited to, sialic acid, zanamivir, oseltamivir, amantadine, rimantadine, and combinations thereof. The polymer is preferably a water-soluble, biocompatible polymer. Suitable polymers include, but are not limited to, poly(isobutylene-alt-maleic anhydride) (PIBMA), poly(aspartic acid), poly(l-glutamic acid), polylysine, poly(acrylic acid), plyaginic acid, chitosan, carboxymethyl cellulose, carboxymethyl dextran, polyethyleneimine, and blends and copolymers thereof. In another embodiment, the compositions contain a physical mixture of polymer containing one antiviral agent and polymer containing a second antiviral agent. The compositions can be formulated for enteral or parenteral administration. Suitable oral/intranasal dosage forms include, but are not limited to, tablets, capsules, solutions, suspensions, emulsions, syrups, and lozenges. Suitable dosage forms for parenteral administration include, but are not limited to, solutions, suspensions, and emulsions. The compositions described herein are effective at treating a variety of infections, including viral infections such as influenza, while inhibiting or preventing the development of microbial resistance.

The invention belongs to the fields of pharmacy and influenza, and discloses a zanamivir inhalation solution and the application thereof. The zanamivir inhalation solution is prepared by being added with a certain dosage of surface active agent and osmotic pressure regulator, and comprises the components by weight percent: 0.1-10wt percent of zanamivir, 0.01-0.5wt percent of surface active agent, 0.9-8wt % of osmotic pressure regulator and balance water. The inhalation solution is beneficial to forming aerosol granules with small grain diameter by ultrasonic atomization, and prevents the zanamivir liquid drops from merging and gathering after aerosol is formed, thus effectively transmitting the medicine into the lung of a patient, and ensuring the medicine to take the best effect.

The invention relates to the new dosage form of zanamivir, which is a nasal in-situ gel with phase transformation property and preparation methods, the invention is made of the original drug of zanamivir, hydrophilic gel materials which are sensitive to environments and assistant materials which can be accepted in pharmacy, after being absorbed by nasal mucosa, the invention can have systemic functions and improve the partial concentration of drugs in respiratory tracts, when room temperature is about 20 DEG C and the invention is in storing state, the invention is in the state of liquid, while after being put into the physiological conditions of nasal cavities, the invention can be quickly formed into gel on the surface of nasal mucosa, so that the detained time of drugs can be prolonged, biological availability can be improved and the compliance of patients can be perfected, and the viscosity of the invention is proper, after being formed into gel, the invention can be detained on the surface of the nasal cavity for a rather long time, which has no nasal ciliary toxicity.

Methods and compositions for detection of drug resistant pathogens and treatment against infections thereof are provided. Methods for detection of oseltamivir-resistant influenza viruses by competitive binding assays utilizing non-oseltamivir influenza virus neuraminidase inhibitors and oseltamivir carboxylate are provided. Influenza virus neuraminidase inhibitors coupled to sensors and useful for employment in the methods of the invention are disclosed. Novel phosphonate compounds active as neuraminidase inhibitors against wild-type and oseltamivir-resistant influenza strains of H1N1, H5N1 and H3N2 viruses are disclosed. An enantioselective synthetic route to preparation of these phosphonate compounds via sialic acid is provided.

Novel dual-targeted, bifunctional anti-influenza drugs formed by conjugation with anti-inflammatory agents are disclosed. Exemplary drugs according to the invention include caffeic acid (CA)-bearing zanamivir (ZA) conjugates ZA-7-CA (1), ZA-7-CA-amide (7) and ZA-7-Nap (43) for simultaneous inhibition of influenza virus neuraminidase and suppression of proinflammatory cytokines. Synthetic methods for preparation of these enhanced anti-influenza conjugate drugs are provided. The synthetic bifunctional ZA conjugates act synergistically towards protection of mice lethally infected by H1N1 or H5N1 influenza viruses. The efficacy of ZA-7-CA, ZA-7-CA-amide and ZA-7-Nap conjugates is much greater than the combination therapy of ZA with anti-inflammatory agents.

The invention discloses application of neuraminidase and neuraminidase inhibitors to preparation of medicines for inhibiting hepatic gluconeogenesis. Zanamivir and oseltamivir phosphate are effectiveinhibitors of the neuraminidase; the inhibition effect of coptisine on neuraminidase is also disclosed in the previous patent application of the applicant. The applicant also discovers that salvanic acid B is capable of inhibiting the activity of the neuraminidase in vitro and is used as an inhibitor of the neuraminidase. In-vivo test proves that the several neuraminidase inhibitors are capable ofeffectively inhibiting the activity of the neuraminidase in the liver and then inhibiting hepatic gluconeogenesis. Therefore, the neuraminidase and the neuraminidase inhibitors can be used for preparing the medicines for inhibiting hepatic gluconeogenesis and can also be used for treating diabetes, obesity and non-alcoholic fatty liver disease.

The invention discloses a neuraminidase inhibitor zanamivir derivative and a preparation method thereof. Different from the previous synthetic route of zanamivir derivatives, the present invention uses zanamivir as the starting material for the first time to prepare derivatives; the one-step reaction obtains the product, which greatly simplifies the synthesis steps; the prepared compounds are all New compound molecules with high predicted biological activity.

The invention relates to a laninamivir octanoate preparation method, wherein the method is performed in the same reactor or a plurality of reactors in a step-by-step manner. The reaction process sequentially comprises: 1) mixing zanamivir and methanol while adding an acid cation resin, and carrying out a reaction to obtain zanamivir methyl ester; 2) carrying out a reaction of the zanamivir methyl ester and dimethyl carbonate under an alkaline condition to produce a compound represented by a formula (17); 3) carrying out a reaction of the compound represented by the formula (17) and methyl iodide under an alkaline condition to obtain a compound represented by a formula (18); 4) carrying out a reaction of the compound represented by the formula (18) and an alkali, and adopting a cation resin to adjust the pH value to the neutral state to obtain a compound represented by a formula (19); and 5) carrying out a reaction of the compound represented by a formula (19) and octanoyl chloride to obtain the target product laninamivir octanoate. The present invention provides the laninamivir octanoate preparation method, which has characteristics of simple route, low cost, low energy consumption, high product purity, and avoidance of use of hypertoxic reagents and explosive reagents.

The invention provides a sialic acid analog with obvious activity of inhibiting influenza virus and application of the sialic acid analog to preparation of anti-influenza-virus medicaments. Zanamivir serves as a lead compound; and a C6 position side chain in the molecular structure is modified, so that a novel zanamivir analog of which the C6 position is provided with an amino side chain and a C6position side chain is provided with hydrophilic hydroxyl is obtained. A vitro anti-virus activity research is performed on the compound. The result shows that the compound in vitro has obvious activity of inhibiting the influenza virus. Therefore, the sialic acid analog is expected to be applied to preparation of the anti-influenza-virus medicaments.

The invention relates to a preparation method of an antiviral drug zanamivir, which comprises the following steps: amino in an intermediate neuraminic acid methyl ester derivative is conversed to guanidine, then ester group is subjected to hydrolyzation, so that zanamivir is prepared. Compared with current synthesis technology of zanamivir, the method of the invention has the advantages that the usage of resin can be avoided, the cost is reduced, no separation or purification is required after each step of the reaction, the next step reaction can be directly carried out, the loss of the intermediate during the purifying process can be avoided, the yield is high, the operation is convenient, and the preparation method of the zanamivir is suitable for industrial production.

The invention provides application of zanamivir in preparation of a medicine for treating or preventing preeclampsia, a corresponding medicine and a treatment method. Zanamivir can effectively improve the symptoms of hypertension, proteinuria, creatinine, neuraminidase and sialic acid rise of preeclampsia and increase the NO level; the pregnancy outcome is improved. The combination of zanamivir and hydroxyprogesterone hexanoate shows a better effect.